Page last updated: 2024-08-25

isoalantolactone and Bone Loss, Osteoclastic

isoalantolactone has been researched along with Bone Loss, Osteoclastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, T; Chen, Y; He, R; Hou, W; Kuang, Z; Lu, J; Tang, L; Ye, C	1

Other Studies

1 other study(ies) available for isoalantolactone and Bone Loss, Osteoclastic

Article	Year
Isoalantolactone inhibits RANKL-induced osteoclast formation via multiple signaling pathways. International immunopharmacology, 2020, Volume: 84 Topics: Actins; Animals; Bone Resorption; Cathepsin K; Cells, Cultured; Female; Macrophages; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Ovariectomy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-fos; RANK Ligand; Sesquiterpenes; Signal Transduction	2020

Article

Year

Isoalantolactone inhibits RANKL-induced osteoclast formation via multiple signaling pathways.

International immunopharmacology, 2020, Volume: 84

Topics: Actins; Animals; Bone Resorption; Cathepsin K; Cells, Cultured; Female; Macrophages; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Ovariectomy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-fos; RANK Ligand; Sesquiterpenes; Signal Transduction

2020